Savara Faces Securities Class Action Over MOLBREEVI BLA as Lead-Plaintiff Deadline Arrives
The suit claims the filing lacked key chemistry, manufacturing and controls data, creating approval hurdles and heightening financing risk.
Overview
- Multiple investor law firms say a class action has been filed against Savara and certain officers and are urging shareholders to seek lead-plaintiff status by November 7, 2025.
- Notices define a proposed class period spanning March 7, 2024 to May 23, 2025, with some using March 4, 2024 as the start date.
- The complaints allege Savara misled investors about the completeness and timing of its MOLBREEVI Biologics License Application for a rare lung disease therapy.
- Filings assert the alleged deficiencies made FDA approval unlikely in the application’s current form and increased the likelihood the company would need to raise additional capital.
- The firms emphasize that no class has been certified and that investors may participate without serving as lead plaintiff or paying out-of-pocket fees.